Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

被引：11
作者：
Antonioli, Elisabetta [1 ]
Staderini, Michela [1 ]
Pilerci, Sofia [1 ]
Perfetto, Federico [2 ]
Cappelli, Francesco [2 ]
Allinovi, Marco [2 ,3 ]
Nozzoli, Chiara [4 ]
Attucci, Irene [1 ]
Buzzichelli, Alessandra [1 ]
Messeri, Maria [1 ]
Bosi, Alberto [1 ]
机构：
[1] Careggi Univ Hosp, Haematol Unit, Largo Brambilla 3, I-50134 Florence, Italy
[2] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Florence, Italy
[3] Careggi Hosp, Nephrol Dialysis & Transplantat Unit, Florence, Italy
[4] Careggi Univ Hosp, Cell Therapy & Transfus Med Unit, Florence, Italy
来源：
LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 13期
关键词：
REFRACTORY MULTIPLE-MYELOMA; MONOTHERAPY;
D O I：
10.1080/10428194.2020.1802452
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3255 / 3258
页数：4
相关论文
共 14 条
  • [1] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    [J]. LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [2] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    [J]. ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
  • [3] Organ responses with daratumumab therapy in previously treated AL amyloidosis
    Chung, Alfred
    Kaufman, Gregory P.
    Sidana, Surbhi
    Eckhert, Erik
    Schrier, Stanley L.
    Lafayette, Richard A.
    Arai, Sally
    Witteles, Ronald M.
    Liedtke, Michaela
    [J]. BLOOD ADVANCES, 2020, 4 (03) : 458 - 466
  • [4] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
    de Weers, Michel
    Tai, Yu-Tzu
    van der Veer, Michael S.
    Bakker, Joost M.
    Vink, Tom
    Jacobs, Danielle C. H.
    Oomen, Lukas A.
    Peipp, Matthias
    Valerius, Thomas
    Slootstra, Jerry W.
    Mutis, Tuna
    Bleeker, Wim K.
    Anderson, Kenneth C.
    Lokhorst, Henk M.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (03) : 1840 - 1848
  • [5] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Dimopoulos, M. A.
    Oriol, A.
    Nahi, H.
    San-Miguel, J.
    Bahlis, N. J.
    Usmani, S. Z.
    Rabin, N.
    Orlowski, R. Z.
    Komarnicki, M.
    Suzuki, K.
    Plesner, T.
    Yoon, S. -S.
    Ben Yehuda, D.
    Richardson, P. G.
    Goldschmidt, H.
    Reece, D.
    Lisby, S.
    Khokhar, N. Z.
    O'Rourke, L.
    Chiu, C.
    Qin, X.
    Guckert, M.
    Ahmadi, T.
    Moreau, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) : 1319 - 1331
  • [6] Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
    Jullien, Maxime
    Trudel, Sabrina
    Tessoulin, Benoit
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Gastinne, Thomas
    Bonnet, Antoine
    Lok, Anne
    Lebourgeois, Amandine
    Peterlin, Pierre
    Garnier, Alice
    Chevalier, Patrice
    Guillaume, Thierry
    Thomare, Patrick
    Le Gouill, Steven
    Moreau, Philippe
    Touzeau, Cyrille
    [J]. ANNALS OF HEMATOLOGY, 2019, 98 (06) : 1435 - 1440
  • [7] Evaluation of the safety and efficacy of daratumumab outside of clinical trials
    Kobayashi, Hiroki
    Tsushima, Takafumi
    Terao, Toshiki
    Abe, Yoshiaki
    Miura, Daisuke
    Narita, Kentaro
    Kitadate, Akihiro
    Takeuchi, Masami
    Matsue, Kosei
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (06) : 665 - 672
  • [8] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
    Lonial, Sagar
    Weiss, Brendan M.
    Usmani, Saad Z.
    Singhal, Seema
    Chari, Ajai
    Bahlis, Nizar J.
    Belch, Andrew
    Krishnan, Amrita
    Vescio, Robert A.
    Victoria Mateos, Maria
    Mazumder, Amitabha
    Orlowski, Robert Z.
    Sutherland, Heather J.
    Blade, Joan
    Scott, Emma C.
    Oriol, Albert
    Berdeja, Jesus
    Gharibo, Mecide
    Stevens, Don A.
    LeBlanc, Richard
    Sebag, Michael
    Callander, Natalie
    Jakubowiak, Andrzej
    White, Darrell
    de la Rubia, Javier
    Richardson, Paul G.
    Lisby, Steen
    Feng, Huaibao
    Uhlar, Clarissa M.
    Khan, Imran
    Ahmadi, Tahamtan
    Voorhees, Peter M.
    [J]. LANCET, 2016, 387 (10027) : 1551 - 1560
  • [9] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Lovas, Szilvia
    Varga, Gergely
    Farkas, Peter
    Masszi, Tamas
    Wohner, Nikolett
    Bereczki, Agnes
    Adamkovich, Nora
    Borbenyi, Zita
    Szomor, Arpad
    Alizadeh, Hussain
    Szaleczky, Erika
    Wolf, Krisztina
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Csacsovszki, Otto
    Csukly, Zoltan
    Rajnics, Peter
    Egyed, Miklos
    Nagy, Zsolt
    Rejto, Laszlo
    Illes, Arpad
    Mikala, Gabor
    Varoczy, Laszlo
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (05) : 559 - 565
  • [10] Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
    Overdijk, Marije B.
    Verploegen, Sandra
    Bogels, Marijn
    van Egmond, Marjolein
    van Bueren, Jeroen J. Lammerts
    Mutis, Tuna
    Groen, Richard W. J.
    Breij, Esther
    Martens, Anton C. M.
    Bleeker, Wim K.
    Parren, Paul W. H. I.
    [J]. MABS, 2015, 7 (02) : 311 - 320
12